HLB SCIENCE Inc.

A343090

KR7343090007

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 20/05/2024 BST			5-day change	1st Jan Change
2,110 ^KRW	+1.69%		-28.60%	-17.58%

2023	HLB SCIENCE Inc. announced that it has received KRW 6.000000045 billion in funding from HLB Life Science Co., Ltd.	CI
2023	HLB SCIENCE Inc. announced that it expects to receive KRW 6.000000045 billion in funding from HLB Life Science Co., Ltd.	CI

DandiBioscience, Inc. announced that it has received KRW 1.3 billion in funding

April 21, 2021

On April 22, 2021, DandiBioscience, Inc. (XKON:A343090) closed the transaction.

Latest news about HLB SCIENCE Inc.

HLB SCIENCE Inc. announced that it has received KRW 6.000000045 billion in funding from HLB Life Science Co., Ltd.	25/09/23	CI
HLB SCIENCE Inc. announced that it expects to receive KRW 6.000000045 billion in funding from HLB Life Science Co., Ltd.	17/09/23	CI
HLB SCIENCE Inc. announced that it has received KRW 5.0000004 billion in funding from HLB bioStep Co.,Ltd.	08/02/23	CI
HLB SCIENCE Inc. announced that it expects to receive KRW 5.0000004 billion in funding from HLB bioStep Co.,Ltd.	31/01/23	CI
DandiBioscience, Inc. announced that it has received KRW 8.4 billion in funding	06/07/21	CI
DandiBioscience, Inc. announced that it expects to receive KRW 8.4 billion in funding	14/06/21	CI
DandiBioscience, Inc. announced that it has received KRW 1.3 billion in funding	21/04/21	CI
DandiBioscience, Inc. announced that it expects to receive KRW 1.3 billion in funding	15/04/21	CI
NEXT SCIENCE Co.,Ltd. cancelled the acquisition of 45.4% stake in Dandi Bioscience Inc.	04/10/19	CI
Dandi Bio Science Co.,Ltd. announced that it has received KRW 4.164081 billion in funding from Next Science Co., Ltd.	27/03/19	CI
Dandi Bio Science Co.,Ltd. announced that it expects to receive KRW 4.164081 billion in funding from NEXT SCIENCE Co.,Ltd.	21/02/19	CI
Next Science In Talks To Acquire Dandi Bioscience	05/10/18	CI
NEXT SCIENCE Co.,Ltd. agreed to acquire 45.4% stake in Dandi Bioscience Inc. for KRW 6.3 billion.	04/10/18	CI

HLB Science Inc, formerly DanDi Bioscience Inc, is a Korea-based company principally engaged in the research and development of biological pharmaceuticals. The Company is engaged in the research and development of sepsis treatment, antibiotics for super bacteria, dementia treatment, dementia diagnostic kits and other medicines products.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
HLB SCIENCE INC.	-17.58%	25.35M
VERTEX PHARMACEUTICALS INCORPORATED	+8.63%	114B
REGENERON PHARMACEUTICALS, INC.	+13.17%	107B
BIONTECH SE	-12.76%	22.22B
ARGENX SE	-2.50%	21.28B
BEIGENE, LTD.	-7.19%	17.51B
WUXI APPTEC CO., LTD.	-39.93%	17.17B
NEUROCRINE BIOSCIENCES, INC.	+6.67%	14.14B
SAREPTA THERAPEUTICS, INC.	+33.90%	12.2B
LEGEND BIOTECH CORPORATION	-28.60%	7.83B

Bio Therapeutic Drugs

HLB SCIENCE Inc.

Equities

A343090

KR7343090007

Biotechnology & Medical Research

DandiBioscience, Inc. announced that it has received KRW 1.3 billion in funding

Latest news about HLB SCIENCE Inc.

Chart HLB SCIENCE Inc.

Company Profile

Sector Bio Therapeutic Drugs